


5 SALT FORMS OF 3-(4-BROMO-2,6-DIFLUORO-BENZYLOXY)-5-[3-(4-PYRROLIDIN-1-
 YL-BUTYL)-UREIDO]-ISOTHIAZOLE-4-CARBOXYLIC ACID AMIDE AND
 METHOD OF PRODUCTION

Background of the Invention

10 This invention relates to salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide having the formula:



 formula I.

15 Formula I in its free base form is described in co-pending United States Serial No. 09/316,837, filed May 21, 1999, the disclosure of which is hereby incorporated herein by reference in its entirety. The foregoing application is assigned in common with the present application. The free base of formula I is useful in the treatment of hyperproliferative diseases, such as cancers.

 The present invention provides the hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide.

25 The present invention further relates to methods of making the hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide. The invention also relates to pharmaceutical compositions containing the hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salts of the compound of formula I. The salts of the present invention are useful
30 in the treatment of hyperproliferative diseases, such as cancers, in mammals, especially humans. The invention also relates to methods of administering the salts of formula I to treat hyperproliferative diseases.

5

Brief Description of the Drawings

FIG 1. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hydrochloride which was prepared and isolated according to the process of the invention as illustrated in Example 2.

FIG 2. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hydrobromide which was prepared and isolated according to the process of the invention as illustrated in Example 3.

FIG 3. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hemi-citrate which was prepared and isolated according to the process of the invention as illustrated in Example 4.

FIG 4. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide acetate which was prepared and isolated according to the process of the invention as illustrated in Example 5.

FIG 5. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide p-tosylate which was prepared and isolated according to the process of the invention as illustrated in Example 6.

FIG 6. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide L-tartrate which was prepared and isolated according to the process of the invention as illustrated in Example 7.

FIG 7. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hemi-succinate, identified as From A hemi-succinate, which was prepared and isolated according to the process of the invention as illustrated in Example 8.

5

FIG 8. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hemi-succinate, identified as Form B, which was prepared and isolated according to the process of the invention as illustrated in Example 9.

10

FIG 9. is an X-ray powder diffraction spectrum of the of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide mesylate which was prepared and isolated according to the process of the invention as illustrated in Example 10.

15


In the X-ray powder diffraction spectra shown in FIGS. 1-9 the horizontal axis shows the angle of diffraction 2-theta degrees and the vertical axis shows the intensity of diffraction in Cps.

20

Summary of the Invention

The present invention relates to hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide having the following formula:

25



formula I.

The present invention is also directed to processes for preparing the hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salts of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide comprising combining the free base with one of the aforementioned salts in the presence of a suitable organic solvent.

30

The hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salts of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-

5 butyl)-ureido]-isothiazole-4-carboxylic acid amide have been characterized by X-ray powder diffractometry.

The hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate (Forms A and B), and mesylate crystals of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide provide powder X-ray
10 diffraction spectrums substantially the same as the powder X-ray diffraction spectrums shown in FIGS. 1-9, respectively. However, it is known that a powder X-ray diffraction spectrum may be obtained with a measurement error depending on measurement conditions. In particular, it is generally known that intensities in a powder X-ray diffraction spectrum may fluctuate depending on measurement conditions. Therefore, it should be understood that the salts of
15 the present invention are not limited to the crystals that provide X-ray powder diffraction spectrum completely identical to the X-ray powder diffraction spectrums shown in FIGS. 1-8, and that any crystals providing X-ray powder diffraction spectrums substantially the same as the aforementioned X-ray powder diffraction spectrums fall within the scope of the present invention. Those skilled in the field of X-ray powder diffractometry can readily judge the
20 substantial identity of X-ray powder diffraction spectrums.

Generally, a measurement error of diffraction angle for an usual X-ray powder diffractometry is about 5% or less, and such degree of a measurement error should be taken into account as to diffraction angles. Furthermore, it should be understood that intensities may fluctuate depending on experimental conditions.

25 The hydrochloride salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 8.623 [90.7], 12.121 [38.9], 17.298 [95.2], 23.397 [44.7], 23.944 [51.7], 24.119 [62.7], 24.873 [55.7], 25.948 [100], and 28.821 [39.6]. The hydrochloride salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as
30 the X-ray diffraction spectrum shown in FIG. 1.

- 5 The characteristic 2-theta (2θ) values and relative intensity (RI) in percentage for the diffraction spectrum of the hydrochloride salt form of the compound of formula I is shown in Table 1.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
6.225	10.5	17.298	95.2	23.397	44.7	28.821	39.6	33.407	10.4
8.623	90.7	17.868	17.6	23.944	51.7	29.438	19.0	33.778	15.3
12.121	38.9	18.712	17.1	24.119	62.7	30.543	15.3	34.920	10.5
12.522	16.8	18.880	14.2	24.873	55.7	31.144	8.7	35.273	9.4
12.873	6.0	19.549	13.8	25.948	100.0	31.757	8.7	36.321	13.6
14.206	4.7	20.552	8.5	27.216	12.6	32.348	14.6	38.409	15.5
15.951	5.1	21.896	22.2	28.146	6.0	32.640	11.4	39.500	9.9
16.736	12.4								

10

Table 1

- 15 The hydrobromide salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 8.687 [100.0], 12.264 [35.9], 17.374 [42.3], 23.711 [24.0], 24.335 [20.7], and 25.769 [34.3]. The hydrobromide salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in FIG. 2.

The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the hydrobromide salt form of the compound of formula I is shown below in Table 2.

5

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
3.156	2.5	17.374	42.3	23.188	5.6	28.528	6.1	33.256	3.7
4.615	2.4	17.767	5.6	23.711	24.0	28.916	9.4	33.897	7.9
6.331	9.3	18.185	3.2	24.335	20.7	29.418	7.7	34.628	2.8
8.687	100.0	18.913	16.6	25.435	9.1	30.266	4.6	34.999	3.3
12.264	35.9	19.528	9.5	25.769	34.3	31.561	3.9	35.432	6.1
12.890	2.2	20.286	2.5	26.940	4.1	32.082	3.4	36.006	4.3
13.445	1.4	20.581	2.9	27.345	7.0	32.638	5.3	37.361	3.4
14.140	3.4	21.874	13.6	28.160	5.7	32.925	4.4	38.224	4.8
16.083	4.0								

Table 2

10 The hemi-citrate salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 4.306 [79.9], 16.317 [100.0], 20.988 [32.7], 21.476 [30.9], 22.643 [48.7], 23.384 [76.9], 24.891 [76.0], 27.573 [47.9], and 27.840 [32.3]. The hemi-citrate salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in FIG. 3.

15 The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the hemi-citrate salt form of the compound of formula I is shown below in Table 3.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
3.201	14.3	13.766	12.4	18.693	15.8	24.217	28.8	29.630	17.4
4.306	79.9	14.086	7.0	19.344	23.4	24.891	76.0	31.251	14.6
6.429	7.0	14.710	9.5	20.394	16.4	25.320	20.4	31.848	14.2
8.620	6.0	15.297	16.0	20.988	32.7	25.948	28.0	32.235	11.8
9.589	5.6	16.317	100.0	21.476	30.9	26.370	25.7	34.147	11.0
10.583	6.8	17.309	14.4	21.994	27.3	27.573	47.9	35.878	16.2
11.449	20.9	17.572	16.5	22.643	48.7	27.840	32.3	37.337	12.3
12.300	8.7	18.258	13.7	23.384	76.9	28.609	19.6		

Table 3

5 The acetate salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 6.096 [21.7], 12.183 [21.4], 17.451 [33.3], 18.288 [100.0], 22.441 [57.7], 23.086 [19.9], and 24.439 [20.7]. The acetate salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in
10 FIG. 4.

The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the acetate salt form of the compound of formula I is shown below in Table 4.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
6.096	21.7	16.793	4.5	21.346	8.9	27.930	5.8	32.271	4.1
8.625	2.8	17.121	12.8	22.441	57.7	28.820	10.0	33.127	5.1
11.840	2.9	17.451	33.3	23.086	19.9	29.648	6.1	35.030	3.4
12.183	21.4	17.920	8.7	24.038	7.5	30.634	3.3	36.445	3.2
14.836	4.2	18.288	100.0	24.439	20.7	31.112	3.2	37.830	3.0
15.264	9.2	20.088	3.6	24.760	11.3	31.951	2.9	39.478	2.5
15.824	5.0	20.458	11.3	25.861	5.0				

15 Table 4

The p-tosylate salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 20.446 [100.0], 20.760 [74.0], 22.092 [81.7], 22.371 [70.8], 23.190 [65.2],
20 and 26.239 [61.5]. The p-tosylate salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in FIG. 5.

The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the p-tosylate salt form of the compound of formula I is shown below in Table 5.

5

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
6.817	50.3	13.373	53.9	18.174	21.3	23.190	65.2	28.167	34.5
7.515	28.0	14.337	18.3	18.976	40.4	24.110	30.5	29.672	19.6
7.822	22.3	15.001	22.2	19.739	36.7	25.471	40.2	31.038	19.3
11.157	15.0	15.601	21.4	20.446	100.0	25.932	50.4	31.586	21.2
12.205	24.5	16.297	14.0	20.760	74.0	26.239	61.5	35.357	19.6
12.800	30.0	16.943	32.0	22.092	81.7	27.355	48.8	36.800	16.4
13.047	43.6	17.362	23.5	22.371	70.8	27.833	39.0		

Table 5

The L-tartrate salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 4.061 [82.9], 20.821 [85.6], 21.634 [100.0], 22.179 [94.0], and 25.858 [95.1]. The L-tartrate salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in FIG. 6.

The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the L-tartrate salt form of the compound of formula I is shown below in Table 6.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
4.061	82.9	14.631	27.2	20.010	53.0	24.788	53.8	32.465	36.1
6.678	11.8	15.428	22.7	20.334	58.7	25.081	60.9	33.442	33.7
8.057	29.4	16.143	31.2	20.821	85.6	25.858	95.1	34.090	34.6
9.383	8.7	16.853	65.3	21.634	100.0	26.803	59.6	34.642	26.8
10.647	8.3	17.338	56.2	22.179	94.0	28.386	34.3	35.635	33.7
11.711	60.2	18.400	97.0	22.730	73.8	29.067	34.1	36.073	28.5
12.075	27.4	18.639	98.2	23.477	77.1	29.844	30.5	36.771	24.5
12.868	33.8	18.994	52.4	24.257	67.8	31.309	39.4	38.080	22.6
13.320	22.7	19.722	42.9						

Table 6

The anhydride hemi-succinate crystals of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide were found to have

5 hygroscopic properties at humidity conditions of 90%. Two crystal forms of hemi-succinate crystals of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide were identified. Hemi-succinate crystal form A of the compound of formula I was found to have a 0.6 % w/w hygroscopicity at 30°C and 90% RH. Hemi-succinate crystal form B of the compound of formula I was found to have a 1.5 % w/w
10 hygroscopicity at 30°C and 90% RH. Hemi-succinate form B is converted into the hemi-succinate form A in refluxing ethanol in less than 24 hours. Hemi-succinate salt forms A and B of the present invention provide X-ray powder diffraction spectrums substantially the same as the X-ray diffraction spectrums shown in FIGS. 7 and 8, respectively.

The hemi-succinate salt form A of the compound of formula I is characterized in that
15 the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 4.634 [100.0], 16.735 [67.2], 22.179 [60.8], and 25.002 [70.3].

The hemi-succinate salt form B of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 6.714 [31.0], 15.272 [100.0], 19.197 [59.3], 19.457 [50.0], 24.487 [99.0], and
20 24.802 [79.1].

The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrums of hemi-succinate salt forms A and B of the compound of formula I are shown below in Tables 7 and 8, respectively.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
4.634	100.0	13.683	13.8	17.760	20.6	22.866	38.7	27.609	23.7
6.149	15.5	14.440	13.5	18.679	18.4	23.255	39.5	30.106	14.3
9.843	6.2	14.896	21.9	19.421	30.2	24.079	44.6	30.797	13.7
11.392	11.3	15.996	14.4	20.586	29.2	25.002	70.3	37.769	11.4
11.937	19.2	16.735	67.2	22.179	60.8	26.549	26.8		

Table 7

5

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
6.714	31.0	15.272	100.0	19.197	59.3	24.487	99.0	29.732	14.1
8.666	7.3	15.813	19.8	19.457	50.0	24.802	79.1	30.796	17.5
11.092	8.6	16.551	17.5	20.597	17.2	25.640	15.9	33.484	9.4
11.696	21.9	16.875	26.4	21.160	28.8	26.641	20.1	34.594	11.4
12.008	15.9	17.365	12.6	21.648	21.7	27.090	15.1	37.212	15.5
12.630	7.3	17.986	8.6	22.988	15.0	27.843	21.5	37.905	8.9
13.466	17.2	18.710	26.4	23.568	18.6	28.552	19.7	39.023	8.9
13.774	13.9								

Table 8

10 The mesylate salt form of the compound of formula I is characterized in that the crystal provides high-intensity diffraction peaks at diffraction angles of about 2-theta, [% relative intensity]: 4.417 [99.3], 17.288 [45.5], 20.828 [39.6], 21.677 [43.5], 22.148 [68.3], 25.427 [100.0], and 27.006 [37.5]. The mesylate salt form of the present invention provides a X-ray powder diffraction spectrum substantially the same as the X-ray diffraction spectrum shown in FIG. 9.

15 The characteristic 2-theta (2θ) values and relative intensity (%) for the diffraction spectrum of the mesylate salt form of the compound of formula I is shown below in Table 9.

2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)	2θ	RI(%)
4.417	99.3	15.619	9.1	21.677	43.5	27.006	37.5	32.337	9.0
8.806	7.2	17.288	45.5	22.148	68.3	28.757	8.8	32.940	7.8
11.664	7.0	17.654	17.2	23.231	14.1	29.564	6.7	33.796	11.8
12.267	18.7	17.993	15.9	23.966	28.8	30.560	6.2	34.550	8.7
12.610	8.3	18.728	9.8	24.602	30.2	31.173	9.7	35.308	7.6
13.224	5.4	20.358	15.0	25.427	100.0	31.722	13.3	36.883	9.1
14.915	27.1	20.828	39.6	26.226	16.1				

Table 9

20

X-ray powder diffraction pattern is only one of many ways to characterize the arrangement of atoms comprising the salts of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-

5 pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide. Other methods are well known in the art, such as, single X-ray crystal diffraction, may be used to identify aforementioned salt forms of formula I.

It has unexpectedly been found that the acetate, hydrochloride, hydrobromide, hemi-succinate, and mesylate salt forms of the compound of formula I have high crystallinity, i.e.,
10 substantially free of amorphous material. Such salts have the advantage that they provide more reproducible dosing results. The hydrochloride, hydrobromide, and hemi-succinate salt forms of the compound of formula I are substantially hygroscopically stable, which alleviates potential problems associated with weight changes of the active ingredient during the manufacture of capsules or tablets. The hydrochloride and hydrobromide forms of the
15 compound of formula I have the additional advantage that they have a low tendency for concentrated aqueous solution to form viscous mixtures upon standing. Furthermore, the hydrobromide salt form of the compound of formula I delivers a mild sedative effect at low to moderate dosing. The mesylate salt form of the compound of formula I has rapid kinetic aqueous solubility which simplifies aqueous dosing and makes it suitable for injectable dosage
20 forms. Furthermore, the mesylate salt form of the compound of formula I with enhanced solubility characteristics facilitates the dissolution of solid dosage forms in a timely manner.

The p-tosylate, L-tartrate and hemi-citrate salts have greater kinetic solubility than the free base or hydrochloride form of the compound of formula I. Additionally, the p-tosylate, L-tartrate, and hemi-citrate salts of the compound of formula I are less hygroscopic than the
25 mesylate salt of the compound of formula I. Accordingly, the p-tosylate, L-tartrate, and hemi-citrate salts of the compound of formula I are more stable in air and can be used without deliquescence.

The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal, which comprises a therapeutically effective amount of a
30 salt of a compound of formula I or a hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, prostate, colorectal, oesophageal, gynecological (such as ovarian) or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a non-cancerous
35 hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH)).

The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) in a mammal which comprises a therapeutically effective amount of a salt of a
40 compound of formula I or hydrate thereof, and a pharmaceutically acceptable carrier.

5 The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a salt of a compound of formula I or hydrate thereof, and a pharmaceutically acceptable carrier.

 The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective
10 amount of a salt of a compound of formula I or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular
15 degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

 The invention also relates to a method of treating a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a salt of a compound of formula I or hydrate thereof. In one embodiment, said method relates to
20 the treatment of cancer such as brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, gynecological (such as ovarian) or thyroid cancer. In another embodiment, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH)).

25 The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a salt of a compound of formula I or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase
30 inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

 The invention also relates to a method of treating pancreatitis or kidney disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a salt of a compound of formula I or hydrate thereof.

35 The invention also relates to a method of preventing blastocyte implantation in a mammal which comprises administering to said mammal a therapeutically effective amount of a salt of a compound of formula I or hydrate thereof.

 The invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal which comprises administering to said mammal an effective amount of a salt of a compound of formula I or hydrate thereof. In one embodiment, said method is for
40 treating a disease selected from the group consisting of tumor angiogenesis, chronic

5 inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

Further the compounds of the present invention may be used as a contraceptive in
10 mammals. In one preferred embodiment the compounds of the present invention may be used to prevent pregnancy in a female mammal.

Patients that can be treated with the salts of formula I and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer,
15 cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the
20 endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumors, brain stem gliomas or
25 pituitary adenomas).

This invention also relates to a pharmaceutical composition for the treatment of an infection in a mammal, including a human, that is facilitated by farnesyl protein transferase, such as malaria or hepatitis delta virus, comprising an amount of a salt of a compound of the formula I, as defined above, a prodrug or solvate thereof, that is effective in treating abnormal cell
30 growth, and a pharmaceutically acceptable carrier.

"Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) expressing an activated Ras oncogene; (2) tumor cells in which the Ras protein is activated as a result of oncogenic mutation
35 in another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs; and (4) any tumors that proliferate by virtue of farnesyl protein transferase.

The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term
40 applies, or one or more symptoms of such disorder or condition. The term "treatment", as used

5 herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.

Detailed Description of the Invention

The present invention relates to hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salts of 3-(4-bromo-2,6-difluoro-benzyloxy)-
10 5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide.

The invention further relates to a method making the hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate, and mesylate salts of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide. The salt forms of the present invention are useful in the treatment of hyperproliferative
15 diseases, such as cancers, in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

The salt forms of the compound of formula I have been characterized using X-ray powder diffractometry. The hydrochloride, hydrobromide, hemi-citrate, acetate, p-tosylate, L-tartrate, hemi-succinate (Form A), hemi-succinate (Form B) and mesylate salts of the
20 compound of formula I provide X-ray powder diffraction patterns substantially the same as shown in FIGS 1-9.

The hydrochloride salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray
25 powder diffraction spectrum of about 8.623, 12.121, 17.298, 23.397, 23.944, 24.119, 24.873, 25.948, and 28.821.

The hydrobromide salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray
30 powder diffraction spectrum of about 8.687, 12.264, 17.374, 23.711, 24.335, and 25.769.

The hemi-citrate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray
35 powder diffraction spectrum of about 4.306, 16.317, 20.988, 21.476, 22.643, 23.384, 24.891, 27.573, and 27.840.

The acetate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 6.096, 12.183, 17.451, 18.288, 22.441, 23.086, and 24.439.

5 The p-tosylate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 20.446, 20.760, 22.092, 22.371, 23.190, and 26.239.

10 The L-tartrate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 4.061, 20.821, 21.634, 22.179 and 25.858.

15 The hemi-succinate (Form A) salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 4.634, 16.735, 22.179, and 25.002. Form A hemi-succinate absorbs 0.6% water at 90% relative humidity.

20 The hemi-succinate (Form B) salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 6.714, 15.272, 19.197, 19.457, 24.487, and 24.802. Form B hemi-succinate absorbs 1.5% water at 90% relative humidity.

25 The mesylate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide of the present invention is characterized in that the crystal provides high intensity diffraction peaks at diffraction angles (2θ) in a X-ray powder diffraction spectrum of about 4.417, 17.288, 20.828, 21.677, 22.148, 25.427, and 27.006.

 The *in vitro* activity of the compounds of formula I in inhibiting the KDR/VEGF receptor may be determined by the following procedure.

30 The ability of the compounds of the present invention to inhibit tyrosine kinase activity may be measured using a recombinant enzyme in an assay that measures the ability of compounds to inhibit the phosphorylation of the exogenous substrate, polyGluTyr (PGT, Sigma™, 4:1). The kinase domain of the human KDR/VEGF receptor (amino acids 805-1350) is expressed in Sf9 insect cells as a glutathione S-transferase (GST)-fusion protein using the baculovirus expression system. The protein is purified from the lysates of these cells using glutathione agarose affinity columns. The enzyme assay is performed in 96-well plates that are coated with the PGT substrate (0.625 μ g PGT per well). Test compounds are diluted in dimethylsulfoxide (DMSO), and then added to the PGT plates so that the final concentration of DMSO in the assay is 1.6% (v/v). The recombinant enzyme is diluted in phosphorylation buffer (50 mM Hepes, pH 7.3, 125 mM NaCl, 24 mM $MgCl_2$). The reaction is initiated by the
40 addition of ATP to a final concentration of 10 μ M. After a 30 minute incubation at room

5 temperature with shaking, the reaction is aspirated, and the plates are washed with wash
buffer (PBS-containing 0.1% Tween-20). The amount of phosphorylated PGT is quantitated
by incubation with a HRP-conjugated (HRP is horseradish peroxidase) PY-54 antibody
(Transduction Labs), developed with TMB peroxidase (TMB is 3,3',5,5'-tetramethylbenzidine),
and the reaction is quantitated on a BioRad™ Microplate reader at 450 nM. Inhibition of the
10 kinase enzymatic activity by the test compound is detected as a reduced absorbance, and the
concentration of the compound that is required to inhibit the signal by 50% is reported as the
IC₅₀ value for the test compound.

To measure the ability of the compounds to inhibit KDR tyrosine kinase activity for the
full length protein that exists in a cellular context, the porcine aortic endothelial (PAE) cells
15 transfected with the human KDR (Waltenberger et al., J. Biol. Chem. 269:26988, 1994) may
be used. Cells are plated and allowed to attach to 96-well dishes in the same media (Ham's
F12) with 10% v/v FBS (fetal bovine serum). The cells are then washed, re-fed with serum
depleted media (0.1% v/v FBS) that contains 0.1% (v/v) bovine serum albumin (BSA), and
allowed to incubate for 16-24 hours. Immediately prior to dosing with compound, the cells are
20 re-fed with the serum depleted media (0.1% v/v FBS) (without BSA). Test compounds,
dissolved in DMSO, are diluted into the media (final DMSO concentration 0.5% (v/v)). At the
end of a 2 hour incubation, VEGF₁₆₅ (50 ng/ml final) is added to the media for an 8 minute
incubation. The cells are washed and lysed in 50 μ lysis buffer containing 20 mM Tris-HCL
(pH 8), 150 mM NaCl, 1% v/v NP40, 2 mM NaVO₄, 500 μ M EDTA, 1 mM PMSF, and 1
25 tablet/25 ml EDTA free complete® Protease Inhibitor Table, Roche. The cell lysates is then
diluted to a final volume of 150 μ l in PBS/1 mM NaVO₄. The extent of phosphorylation of KDR
is measured using an ELISA assay. Reactibind Goat-anti Rabbit plates (Pierce) are blocked
with Superblock buffer (Pierce) prior to addition of the anti-flk-1 C-20 antibody (0.5 μ g per well,
Santa Cruz). Any unbound antibody is washed off the plates prior to addition of 100 μ l cell
30 lysate. After a 2 hour incubation of the lysates with the flk-1 antibody, the KDR associated
phosphotyrosine is quantitated by development with the HRP-conjugated PY-54 antibody and
TMB, as described above. The ability of the compounds to inhibit the VEGF-stimulated
autophosphorylation reaction by 50%, relative to VEGF-stimulated controls is reported as the
IC₅₀ value for the test compound.

35 The ability of the compounds to inhibit mitogenesis in human endothelial cells is
measured by their ability to inhibit ³H-thymidine incorporation into HUVE cells (human
umbilical vein endothelial cells, Clonetics™). This assay has been well described in the
literature (Waltenberger J et al. J. Biol. Chem. 269: 26988, 1994; Cao Y et al. J. Biol. Chem.
271: 3154, 1996). Briefly, 10⁴ cells are plated in collagen-coated 24-well plates and allowed

5 to attach. Cells are re-fed in serum-free media, and 24 hours later are treated with various concentrations of compound (prepared in DMSO, final concentration of DMSO in the assay is 0.2% v/v), and 2-30 ng/ml VEGF₁₆₅. During the last 3 hours of the 24 hour compound treatment, the cells are pulsed with ³H thymidine (NEN, 1 μCi per well). The media are then removed, and the cells washed extensively with ice-cold Hank's balanced salt solution, and
10 then 2 times with ice cold trichloroacetic acid (10% v/v). The cells are lysed by the addition of 0.2 ml of 0.1 N NaOH, and the lysates transferred into scintillation vials. The wells are then washed with 0.2 ml of 0.1 N HCl, and this wash is then transferred to the vials. The extent of ³H thymidine incorporation is measured by scintillation counting. The ability of the compounds to inhibit incorporation by 50%, relative to control (VEGF treatment with DMSO vehicle only) is
15 reported as the IC₅₀ value for the test compound.

The activity of the compounds of formula 1 *in vivo*, can be determined by the amount of inhibition of tumor growth by a test compound relative to a control. The tumor growth inhibitory effects of various compounds are measured according to the methods of Corbett T. H., et al. "Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure", Cancer Res., 35, 2434-2439 (1975) and Corbett, T. H., et al., "A Mouse Colon-tumor Model for Experimental Therapy", Cancer Chemother. Rep. (Part 2)", 5, 169-186 (1975), with slight modifications. Tumors are induced in the left flank by s.c. injection of 1 X 10⁶ log phase cultured tumor cells (human MDA-MB-468 breast or human HN5 head and neck carcinoma cells) suspended in 0.10 ml RPMI
20 1640. After sufficient time has elapsed for the tumors to become palpable (2-3 mm in diameter) the test animals (athymic mice) are treated with active compound (formulated by dissolution in DMSO typically at a concentration of 50 to 100 mg/mL followed by 1:9 dilution into saline or, alternatively, 1:9 dilution into 0.1% Pluronic™ P105 in 0.9% saline) by the intraperitoneal (ip) or oral (po) routes of administration twice daily (i.e., every 12 hours) for 5 consecutive days. In
25 order to determine an anti-tumor effect, the tumor is measured in millimeters with Vernier calipers across two diameters and the tumor size (mg) is calculated using the formula: Tumor weight = (length x [width]²)/2, according to the methods of Geran, R.I., et al. "Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems", Third Edition, Cancer Chemother. Rep., 3, 1-104 (1972). Results are expressed as
30 percent inhibition, according to the formula: Inhibition (%) = (TuW_{control} - TuW_{test})/TuW_{control} x 100%. The flank site of tumor implantation provides reproducible dose/response effects for a variety of chemotherapeutic agents, and the method of measurement (tumor diameter) is a reliable method for assessing tumor growth rates.

Administration of the compounds of the present invention (hereinafter the "active
40 compound(s)") can be effected by any method that enables delivery of the compounds to the site

5 of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.

The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration and the judgement of the prescribing physician. However, an effective dosage is in the range of about 10 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may 15 be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and 20 cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example 25 interferon; and anti-hormones, for example anti-estrogens such as Nolvadex™ (tamoxifen) or, for example anti-androgens such as Casodex™ (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.

The pharmaceutical composition may, for example, be in a form suitable for oral 30 administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical 35 carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

5 Suitable pharmaceutical carriers include inert diluents or fillers, water and various
organic solvents. The pharmaceutical compositions may, if desired, contain additional
ingredients such as flavorings, binders, excipients and the like. Thus for oral administration,
tablets containing various excipients, such as citric acid may be employed together with various
10 disintegrants such as starch, alginic acid and certain complex silicates and with binding agents
such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium
stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid
compositions of a similar type may also be employed in soft and hard filled gelatin capsules.
Preferred materials, therefore, include lactose or milk sugar and high molecular weight
polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration
15 the active compound therein may be combined with various sweetening or flavoring agents,
coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with
diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

 Methods of preparing various pharmaceutical compositions with a specific amount of
active compound are known, or will be apparent, to those skilled in this art. For examples, see
20 Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition
(1975).

 The examples and preparations provided below further illustrate and exemplify the
compounds of the present invention and methods of preparing such compounds. It is to be
understood that the scope of the present invention is not limited in any way by the scope of the
25 following examples and preparations.

 The spectrums in FIGS. 1-9 were recorded using a Siemens $\theta/2\theta$ powder
diffractometer equipped as follows: forty position autosampler, goniometer with fixed slits,
sealed-tude copper (Cu) X-ray source (wavelength 1: 1.54056, wavelength 2: 1.54439), and
Kevex solid state detector. Tube power: 40-mA x 50-kV, or as appropriate. Slits: 1 x 1 x 0.6
30 mm (source, anti-scatter, and detector slits, respectively). Step size: 0.04 degrees in 2 θ .
Time per step: 1 second. Scan start: 3 degrees in 2 θ . Scan stop: 40 degrees in 2 θ .

Example 1

 Free base of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-
35 isothiazole-4-carboxylic acid

 The free base of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-
ureido]-isothiazole-4-carboxylic acid is prepared according to the procedure described in
Example 30 of United States Serial No. 09/316837, filed May 21, 1999, the disclosure of which
40 is hereby incorporated herein by reference in its entirety. Mp 208 °C (DSC). Characteristic X-

- 5 ray powder diffraction peaks (2-theta, [% relative intensity]): 9.314 [100.0], 11.356 [44.8], 15.897 [49.6], 22.059 [84.5], 22.520 [63.3], 22.726 [70.0], 23.927 [67.6], 24.307 [60.5], 25.310 [64.8], and 26.551 [86.6].

Example 2

- 10 Hydrochloride salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide

- 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide (500 mg, 0.939 mmol) was dissolved in EtOH (20 mL) at reflux, allowed
15 to cool to ambient temperature and treated with HCl (0.94 mL of a 1.0 M solution in Et₂O) while swirling flask. The mixture was then shaken gently with heating at 50°C for 3 hours and at ambient temperature for 3 days. The solid was filtered, dried under high vacuum to afford a white solid (468 mg, 0.823 mmol, 82%). Melting point 230°C (DSC). Hygroscopicity: 1% (by weight)) at 90% relative humidity at ambient temperature (RH). Characteristic X-ray powder
20 diffraction peaks (2-theta, [% relative intensity]): 8.623 [90.7], 12.121 [38.9], 17.298 [95.2], 23.397 [44.7], 23.944 [51.7], 24.119 [62.7], 24.873 [55.7], 25.948 [100], and 28.821 [39.6].

Example 3

- 25 Hydrobromide salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid

- Hydrobromic acid (1.0 mL of 47-49% aqueous 8.9 M solution) was added to ~4mL of MeOH and then filled to the 8.9 mL mark with MeOH in a graduated cylinder. Separately, 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic
30 acid (500 mg, 0.939 mmol) was dissolved in CH₂Cl₂ (10 mL) and MeOH (4 mL) and treated with HBr (1.0 mL of the solution described above). This solution was then placed in a diffusion chamber surrounded with Et₂O. After 16 hours, solid was present. The Et₂O was replaced by fresh Et₂O and the diffusion continued overnight. A white solid (529 mg, 0.863 mmol, 86%) was obtained. Melting point 201.0°C (DSC). Hygroscopicity: 0.1 % at 87%
35 relative RH. Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 8.687 [100.0], 12.264 [35.9], 17.374 [42.3], 23.711 [24.0], 24.335 [20.7], and 25.769 [34.3].

5

Example 4

Hemi-citrate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (532 mg, 1.00 mmol), citric acid (96 mg, 0.50 mmol), and MeOH (8 mL) were combined in a 16 mL vial with a septum top and heated, with shaking, at 75°C for 24 hours. The mixture was cooled to ambient temperature and filtered. The solid was washed with MeOH and dried by continued passage of air through the solid. A white solid (530 mg, 0.843 mmol, 84%) was obtained. Melting point 201.7°C (DSC). Hygroscopicity: 0.43 % at 87% relative RH. Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 4.306 [79.9], 16.317 [100.0], 20.988 [32.7], 21.476 [30.9], 22.643 [48.7], 23.384 [76.9], 24.891 [76.0], 27.573 [47.9], and 27.840 [32.3].

Example 5

20 Acetate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (532 mg, 1.00 mmol), acetic acid (57 μ L, 1.0 mmol), and MeOH (3 mL) were combined in a 8 mL vial with a septum top and heated, with shaking, at 75°C for 24 hours. The mixture was cooled to ambient temperature and placed in a chamber with Et₂O. After five hours large crystals were harvested by decanting liquid and washing the solid with MeOH and then Et₂O. The solid was dried by brief passage of air through the solid. A white solid (330 mg, 0.557 mmol, 56%) was obtained. Melting point 175°C (DSC). Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 6.096 [21.7], 12.183 [21.4], 17.451 [33.3], 18.288 [100.0], 22.441 [57.7], 23.086 [19.9], and 24.439 [20.7].

Example 6

35 p-Tosylate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (532 mg, 1.00 mmol), p-toluenesulfonic acid monohydrate (179 mg, 1.00 mmol), MeOH (10 mL), and CH₂Cl₂ (1 mL) were combined and filtered to remove small amount of very fine particulate and washed through with additional CH₂Cl₂ (3 mL). The

5 solution was added to additional CH₂Cl₂ (4 mL) plus MeOH (1 mL) and placed in a diffusion chamber with Et₂O overnight. No crystals were formed so the Et₂O was replaced by pentane overnight. The solid was washed with Et₂O and dried by continued passage of air through the solid. A white solid (572 mg, 0.812 mmol, 81%) was obtained. Melting Point 140 and 174°C (DSC). Hygroscopicity: -0.9% at 87% relative RH. Characteristic X-ray powder diffraction
10 peaks (2-theta, [% relative intensity]): 20.446 [100.0], 20.760 [74.0], 22.092 [81.7], 22.371 [70.8], 23.190 [65.2], 26.239 [61.5].

Example 7

L-tartrate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-
15 ureido]-isothiazole-4-carboxylic acid

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-
carboxylic acid (532 mg, 1.00 mmol), L-tartaric acid (150 mg, 1.00 mmol), and MeOH (8 mL)
were combined in a 16 mL vial with a septum top and heated, with shaking, at 75 °C for 24
20 hours. The mixture was cooled to ambient temperature and filtered. The solid was washed with MeOH and dried by continued passage of air through the solid. A white solid (617 mg, 0.904 mmol, 90%) was obtained. Melting point 206°C (DSC). Hygroscopicity: 0.3% at 100% RH. Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 4.061 [82.9], 20.821 [85.6], 21.634 [100.0], 22.179 [94.0], 25.858 [95.1].

25

Example 8

Hemi-succinate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (Form A)

30 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (532 mg, 1.00 mmol), succinic acid (59 mg, 0.50 mmol), and MeOH (8 mL) were combined in a 16 mL vial with a septum top and heated, with shaking, at 75 °C for 24 hours. The mixture was cooled to ambient temperature and filtered. The solid was washed with MeOH and dried by continued passage of air through the solid. A white solid (500 mg,
35 0.845 mmol, 85%) was obtained. Melting point Form A 216°C (DSC). Hygroscopicity: 0.6 % at 90% relative RH. Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): Form A: 4.634 [100.0], 16.735 [67.2], 22.179 [60.8], and 25.002 [70.3].

Example 9

40 Hemi-succinate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-

5 butyl)-ureido]-isothiazole-4-carboxylic acid (Form B)

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (100 mg) was dissolved with heat in 6 mL EtOH:MeOH (2:1). Succinic acid (11.1 mg, 0.5 eq) dissolved in EtOH was added to the former solution. The mixture was
10 allowed to cool to ambient temperature and stirred for 20 min. The solid was filtered, washed with EtOH, and dried by continued passage of air through the solid. A white solid (80 mg, 70%) was obtained. Hygroscopicity Form B: 1.5 % at 90% relative RH. Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 6.714 [31.0], 15.272 [100.0], 19.197 [59.3], 19.457 [50.0], 24.487 [99.0], and 24.802 [79.1].

15

Example 10

Mesylate salt of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid

3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid (10.9 g, 20.5 mmol) was dissolved in MeOH (150 mL) and cooled to 0°C. In a
20 separate flask, H₃CSO₃H (1.33 mL) was added to MeOH (15 mL) at 0°C. The acid solution was then added dropwise over 10 minutes to the amine starting material solution. The solution was warmed to ambient temperature, filtered to remove minor solid impurities, diluted with Et₂O (1 L) and stirred for 1 h. The mixture was further diluted with hexane (500 mL) and
25 cooled to 0°C with continued stirring. After setting overnight at 0°C, the crystals were filtered, washed with hexane, and sucked dry to afford a white solid (11.1 g, 17.7 mmol, 86%). Characteristic X-ray powder diffraction peaks (2-theta, [% relative intensity]): 4.417 [99.3], 17.288 [45.5], 20.828 [39.6], 21.677 [43.5], 22.148 [68.3], 25.427 [100.0], and 27.006 [37.5].